BIO.DE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:36):

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments...

Stats
今日成交量	100.00
平均成交量	154.00
市值	1.40B
EPS	€0 ( 2024-03-28 )
下一个收益日期	( €0 ) 2024-05-06
Last Dividend	€0.0400 ( 2019-05-08 )
Next Dividend	€0 ( N/A )
P/E	13.00
ATR14	€0 (0.00%)

Biotest AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biotest AG 财务报表

Annual	2023
营收:	€684.60M
毛利润:	€271.90M (39.72 %)
EPS:	€3.21

FY	2023
营收:	€684.60M
毛利润:	€271.90M (39.72 %)
EPS:	€3.21

FY	2022
营收:	€516.10M
毛利润:	€124.90M (24.20 %)
EPS:	€-0.800

FY	2021
营收:	€515.60M
毛利润:	€80.70M (15.65 %)
EPS:	€-1.610

Financial Reports:

No articles found.

Biotest AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Biotest AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.59 - good (75.92%) | Divividend Growth Potential Score: 1.201 - No dividend growth expected in the near future

Information

First Dividend	€0.0667	2000-07-17
Last Dividend	€0.0400	2019-05-08
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	€1.683	--
Avg. Dividend % Per Year	0.00%	--
Score	2	--
Div. Sustainability Score	7.59
Div.Growth Potential Score	1.201
Div. Directional Score	4.40	--

Next Divdend (Est)
(2024-12-30)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
H5E.DE	No Dividend Player	2023-07-10	Annually	0.00%
RAA.DE	Ex Dividend Knight	2023-05-11	Annually	0.00%
BPFG.F	Ex Dividend Junior	2023-09-12	Semi-Annually	0.00%
ITU.DE	Ex Dividend Knight	2023-10-06	Quarterly	0.00%
SYT.DE	Ex Dividend Junior	2023-05-05	Annually	0.00%
DAR.DE	No Dividend Player	2023-07-03	Annually	0.00%
M4N.DE	Ex Dividend Junior	2023-06-07	Sporadic	0.00%
3T70.F	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
VNA.F	Ex Dividend Junior	2023-05-18	Annually	0.00%
ERCG.DE	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.217	1.500	5.65	8.48	[0 - 0.5]
returnOnAssetsTTM	0.107	1.200	6.43	7.71	[0 - 0.3]
returnOnEquityTTM	0.368	1.500	7.02	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.963	0.800	5.18	4.15	[1 - 3]
quickRatioTTM	0.845	0.800	9.74	7.79	[0.8 - 2.5]
cashRatioTTM	0.308	1.500	9.40	10.00	[0.2 - 2]
debtRatioTTM	0.441	-1.500	2.64	-3.97	[0 - 0.6]
interestCoverageTTM	4.47	1.000	9.46	9.46	[3 - 30]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
freeCashFlowPerShareTTM	-0.884	2.00	-0.442	-0.884	[0 - 20]
debtEquityRatioTTM	1.278	-1.500	4.89	-7.33	[0 - 2.5]
grossProfitMarginTTM	0.432	1.000	6.13	6.13	[0.2 - 0.8]
operatingProfitMarginTTM	0.251	1.000	6.98	6.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00251	1.000	-1.125	-1.125	[0.2 - 2]
assetTurnoverTTM	0.493	0.800	-0.0455	-0.0364	[0.5 - 2]
Total Score				7.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.63	1.000	9.03	0	[1 - 100]
returnOnEquityTTM	0.368	2.50	8.09	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.884	2.00	-0.295	-0.884	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.115	1.500	-2.57	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00225	1.000	-2.56	0	[0.1 - 0.5]
Total Score				1.201

Biotest AG

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.